Pure Global

INMUNOENSAYO PARA DETERMINAR ANTICUERPOS IGG ESPECÍFICOS FRENTE A SARS-COV-2 SPIKE. - COFEPRIS Registration 1612R2024 SSA

Access comprehensive regulatory information for INMUNOENSAYO PARA DETERMINAR ANTICUERPOS IGG ESPECÍFICOS FRENTE A SARS-COV-2 SPIKE. (INMUNOENSAYO PARA DETERMINAR ANTICUERPOS IGG ESPECÍFICOS FRENTE A SARS-COV-2 SPIKE.) in the Mexico medical device market through Pure Global AI's free database. This Clase II medical device is registered under COFEPRIS analysis ID 1612R2024 SSA and manufactured by KABLA COMERCIAL, S.A. DE C.V.. The device was registered on May 30, 2024.

This page provides complete registration details including product type (III. Agentes de diagnóstico), manufacturer information, and regulatory compliance data from the official Mexico COFEPRIS medical device database. Pure Global AI offers free access to Mexico's complete medical device registry with bilingual Spanish/English support, helping global MedTech companies navigate COFEPRIS regulations efficiently.

Free Database
Powered by Pure Global AI
COFEPRIS Official Data
Clase II
1612R2024 SSA
INMUNOENSAYO PARA DETERMINAR ANTICUERPOS IGG ESPECÍFICOS FRENTE A SARS-COV-2 SPIKE.
COFEPRIS Analysis ID: 1612R2024 SSA
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Device Classification
Risk Class / Clase de Riesgo
Clase II
Product Type (Spanish)
III. Agentes de diagnóstico
Product Type (English)
III. Agentes de diagnóstico
Trade Name (Spanish)
COVID-19 SPIKE QUANTITATIVE VIRCLIA® IGG MONOTEST
Trade Name (English)
COVID-19 SPIKE QUANTITATIVE VIRCLIA® IGG MONOTEST
Registration Information
Analysis ID
1612R2024 SSA
Registration Date
May 30, 2024
Manufacturer / Fabricante
Name (English)
KABLA COMERCIAL, S.A. DE C.V.